<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    UroGen Pharma Ltd.

    UroGen Pharma Ltd.

    UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...

    UroGen Pharma Ltd. is a clinical-stage biopharm...

    Filing Type:    PU
    Atossa Genetics Inc.

    Atossa Genetics Inc.

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is...

    Filing Type:    PU

    Connectyx Technologies Holdings Group, Inc.

    Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...

    Connectyx Technologies Holdings Group, Inc. pro...

    Filing Type:    PU
    Viveve Medical, Inc.

    Viveve Medical, Inc.

    Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...

    Viveve, Inc., the wholly owned subsidiary of Vi...

    Filing Type:    PU
    Dynatronics Corporation

    Dynatronics Corporation

    Dynatronics is a leading medical device company committed to providing high-qualit...

    Dynatronics is a leading medical device company...

    Filing Type:    PU
    Axonics Modulation Technologies, Inc.

    Axonics Modulation Technologies, Inc.

    Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology compan...

    Axonics Modulation Technologies, Inc. (NASDAQ:A...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...

    Iovance Biotherapeutics (formerly traded as Lio...

    Filing Type:    PU
    Anixa Biosciences, Inc.

    Anixa Biosciences, Inc.

    Anixa is focused on harnessing the body’s immune system in the fight against can...

    Anixa is focused on harnessing the body’s imm...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.